What is the right dose? The elusive optimal biologic dose in phase I clinical trials

被引：76

作者：

Adjei, Alex A. ^{[1
]}

机构：

[1] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 25期

关键词：

D O I：

10.1200/JCO.2006.07.4658

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：4054 / 4055

页数：2

共 8 条

[1]

Adjei Alex A., 2006, P249, DOI 10.1016/B978-012088561-9/50011-9

[2] Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer [J].

Carducci, Michael A. ;

Musib, Luna ;

Kies, Merrill S. ;

Pili, Roberto ;

Truong, Mylene ;

Brahmer, Julie R. ;

Cole, Patricia ;

Sullivan, Rana ;

Riddle, Jeanne ;

Schmidt, Jill ;

Enas, Nathan ;

Sinha, Vikram ;

Thornton, Donald E. ;

Herbst, Roy S. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (25) :4092-4099

[3] Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies [J].

LoRusso, PM ;

Adjei, AA ;

Varterasian, M ;

Gadgeel, S ;

Reid, J ;

Mitchell, DY ;

Hanson, L ;

DeLuca, P ;

Bruzek, L ;

Piens, J ;

Asbury, P ;

Van Becelaere, K ;

Herrera, R ;

Sebolt-Leopold, J ;

Meyer, MB .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5281-5293

[4] Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice [J].

Parulekar, WR ;

Eisenhauer, EA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (13) :990-997

[5] Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity [J].

Shaked, Y ;

Emmenegger, U ;

Man, S ;

Cervi, D ;

Bertolini, F ;

Ben-David, Y ;

Kerbel, RS .

BLOOD, 2005, 106 (09) :3058-3061

[6]

Simon R, 2005, CANC TREAT, V123, P339

[7]

SKIPPER H E, 1964, Cancer Chemother Rep, V35, P1

[8]

SKIPPER HE, 1970, CANCER CHEMOTH REP 1, V54, P431

← 1 →